Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
injection site is very itchy; injection site is painful; injection site is red and looks like a rash; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site itching in a patient who received Herpes zoster (Shingrix) for prophylaxis. On 28-APR-2025, the patient received Shingrix. In APR-2025, less than a week after receiving Shingrix, the patient experienced injection site itching (Verbatim: injection site is very itchy), injection site pain (Verbatim: injection site is painful) and injection site rash (Verbatim: injection site is red and looks like a rash). The outcome of the injection site itching, injection site pain and injection site rash were unknown. It was unknown if the reporter considered the injection site itching, injection site pain and injection site rash to be related to Shingrix. It was unknown if the company considered the injection site itching, injection site pain and injection site rash to be related to Shingrix. Additional Information: GSK Receipt Date: 30-APR-2025 Patient had received the vaccine on Monday. By wednesday, the injection site had become very itchy, red, and painful, and it had appeared as a rash.